Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 4
1968 3
1969 3
1970 4
1971 1
1972 1
1973 1
1975 3
1976 1
1978 4
1979 2
1981 2
1982 1
1984 1
1985 1
1986 2
1988 1
1989 3
1990 3
1991 1
1992 4
1993 2
1994 2
1995 1
1996 1
1998 1
2003 1
2004 3
2005 1
2008 1
2012 1
2020 4
2021 11
2022 14
2023 12
2024 9
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.
Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Norén GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C. Fusaroli M, et al. Drug Saf. 2024 Jun;47(6):585-599. doi: 10.1007/s40264-024-01423-7. Epub 2024 May 7. Drug Saf. 2024. PMID: 38713347 Free PMC article.
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement.
Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Norén GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C. Fusaroli M, et al. Drug Saf. 2024 Jun;47(6):575-584. doi: 10.1007/s40264-024-01421-9. Epub 2024 May 7. Drug Saf. 2024. PMID: 38713346 Free PMC article.
Interpretation of Pharmacovigilance Disproportionality Analyses.
Khouri C, Fusaroli M, Salvo F, Raschi E. Khouri C, et al. Among authors: fusaroli m. Clin Pharmacol Ther. 2023 Oct;114(4):745-746. doi: 10.1002/cpt.2951. Epub 2023 May 30. Clin Pharmacol Ther. 2023. PMID: 37248829 No abstract available.
Transparency and robustness of safety signals.
Khouri C, Fusaroli M, Salvo F, Raschi E. Khouri C, et al. Among authors: fusaroli m. BMJ. 2022 Nov 3;379:o2588. doi: 10.1136/bmj.o2588. BMJ. 2022. PMID: 36328354 No abstract available.
113 results